US Patent Issued to TCR2 THERAPEUTICS on Oct. 27 for "Compositions and methods for TCR reprogramming using CD70 specific fusion proteins" (Massachusetts Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,452, issued on Oct. 27, was assigned to TCR2 THERAPEUTICS INC. (Cambridge, Mass.).

"Compositions and methods for TCR reprogramming using CD70 specific fusion proteins" was invented by Robert Hofmeister (Scituate, Mass.), Dario Gutierrez (Waltham, Mass.), Andrew Collard (Boston), Jason Lajoie (Brighton, Mass.), Vania E. Ashminova (North Billerica, Mass.), Michael Lofgren (Watertown, Mass.), Amy Watt (East Bridgewater, Mass.), Derrick McCarthy (Cambridge, Mass.) and Robert Tighe (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are T cell receptor (TCR) fusion proteins (TFPs) comprising CD70 binding domains, T cells engi...